Entries by Roger Tatoud

IAS statement: Imbokodo trial must compel us to adequately resource efforts to find an HIV vaccine

Yesterday Johnson and Johnson and its global partners announced that they would discontinue the large-scale Imbokodo HIV Vaccine Trial.  Initial results showed that the vaccine did not provide significant protection against HIV infection in young women in sub-Saharan Africa. Despite this disappointing news, IAS – the International AIDS Society – emphasizes the importance of continued investment […]

18 May 2021 – HIV Vaccine Awareness Day

Today, the Journal of the International AIDS Society (JIAS) commemorates HIV Vaccine Awareness Day and reflects on the long-standing efforts to develop an HIV vaccine and the significance of SARS-CoV-2 vaccine development over the past year for the future of HIV vaccine research.

How HIV Vaccine R&D is enabling the rapid COVID-19 vaccine response

In this presentation, Dr. Roger Tatoud, presents the finding of an investigation led by the Enterprise to identify and characterize the ways in which HIV vaccine R&D has contributed to the early success of the COVID-19 vaccine response, the extent to which it has contributed across various dimensions, and the uniqueness of its contributions relative to other fields.

HIV R4P Virtual News

HIV vaccine highlights and spotlights – To help attendees manage their time and navigate a busy programme, the Enterprise has developed an HIV vaccine R&D roadmap which covers active immunization and  passive immunization with broadly neutralizing antibodies (bNAbs), especially VRC01.